Testing a new combination for AML with high blast cells
Part of Blood & lymphatic, Cancer clinical trials.
This trial is testing a combination of venetoclax and azacitidine in people with acute myeloid leukemia (AML) who have a high percentage of blast cells (at least 20%) in their bone marrow or blood. It aims to see if this treatment approach can improve outcomes for patients regardless of previous treatments or transplant history.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have a confirmed diagnosis of AML based on standard classification systems.
- You have at least 20% blast cells in your bone marrow or blood from a test done within the last 12 weeks.
- Your doctor plans to start you on a treatment combination called venetoclax and azacitidine.
- You are willing to sign an informed consent form.
- You do not have any other condition that the study doctor thinks would make participation unsafe or difficult.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, venetoclax and a hypomethylating agent, as the first treatment for adults newly diagnosed with acute myeloid leukemia (AML). The goal is to see if this combination works well and is safe.
This trial tests a new drug called CLN-049 combined with two standard treatments (azacitidine and venetoclax) for people with newly diagnosed acute myeloid leukemia (AML) who cannot have strong chemotherapy. The goal is to see if this combination is safe and effective.
This trial tests a combination of chemotherapy drugs (venetoclax, cladribine, cytarabine, and azacitidine) for people newly diagnosed with specific types of acute myeloid leukemia (AML) who cannot have or choose not to have standard intensive chemotherapy.
This trial tests a new combination of drugs (ABC-14) against the standard treatment for adults newly diagnosed with acute myeloid leukemia (AML) who haven't had intensive treatment yet. The goal is to see if the new combo works better and is safe.
This early-phase trial tests whether azacitidine (CC-486) plus venetoclax can help people with acute myeloid leukemia (AML) that is not APL. It’s designed to find safe dosing and see how well the combination works for newly diagnosed or relapsed/refractory AML.
This trial tests a combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a donor stem cell transplant for people with intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach can improve outcomes for patients who have not been treated before.
Hear when a new AML - Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.